Stage IB-IIIB NSCLC, Stage IIB-III NSCLC
Conditions
Keywords
Toripalimab, MRD, Adjuvant therapy
Brief summary
This is a two-cohort, multicenter, Phase II study to evaluate the efficacy and safety of 3-4 cycles of toripalimab (JS001) plus chemotherapy followed by toripalimab maintenance treatment up to one year in participants with completely resected non-small cell lung cancer (NSCLC) stratified by prior neoadjuvant treatment status, as measured by disease-free survival (DFS) and overall survival (OS). Researchers will compare outcomes between two cohorts: 1. Cohort 1: Stage IB-IIIB participants following completely resection without neoadjuvant therapy; 2. Cohort 2: Stage IIB-III participants with non-MPR or MPR but lymph node positivity after neoadjuvant therapy.
Interventions
DRUGToripalimab
Participants will receive Toripalimab (240 mg IV) Q3W for 17 cycles (cycle length=21 days).
Cisplatin\[75 mg/m\^2 IV Q3W\]/carboplatin\[AUC 5 IV Q3W\]+paclitaxel\[260 mg/m\^2 IV Q3W\] or cisplatin\[75 mg/m\^2 IV Q3W)\]/carboplatin\[AUC 5 IV Q3W\]+ pemetrexed\[500 mg/m2 IV Q3W\],dependent on tumor histology. Participants will receive Chemotherapy for 3-4 cycles
Sponsors
Shanghai Junshi Bioscience Co., Ltd.
Wen-zhao ZHONG
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Signed Informed Consent Form 2. Patient with age ≥ 18 and ≤75 years old, gender is not limited. 3. Cohort 1: Histological diagnosis of Stage IB -IIIB NSCLC without anti-cancer treatment; Cohort 2: Histological diagnosis of Stage IIB-III NSCLC with non-MPR or MPR but lymph node positivity after neoadjuvant chemoimmunotherapy; (per American Joint Committee on Cancer staging system (AJCC) staging system, 8th edition) 4. Participants must have had complete resection of NSCLC 60 days 5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 6. Adequate organ function performed within 10 days of treatment initiation 7. Male or female patients of childbearing potential will voluntarily use an effective method of contraception, e.g., double-barrier contraception, condoms, oral or injectable contraceptives, IUDs, etc., during the study period and for the last 6 months of study drug use. All female patients will be considered of childbearing potential unless the female patient is naturally menopausal, artificially menopausal or sterilised (e.g. hysterectomy, bilateral adnexectomy or radiation ovarian irradiation).
Exclusion criteria
1. Pathological histology confirmed the diagnosis of small cell lung cancer pathological type; 2. Treatment with prior systemic chemotherapy at any time 3. Confirmed EGFR or ALK mutations 4. Patient has a history of active autoimmune disease or autoimmune disease that may recur 5. Active hepatitis B and C patients will need to be on relevant antiviral therapy, have HBV-DNA \<2000 IU/ml (\<104 copies/ml) and have received anti-HBV therapy for at least 14 days prior to study participation, and continue therapy for the duration of the treatment period; HCV RNA-positive patients must be on antiviral therapy and have a liver function that is within the elevated CTCAE grade 1; 6. Known allergy to chemotherapy drugs including cisplatin, paclitaxel, albumin-paclitaxel and pemetrexed; 7. History of allergy to monoclonal antibody drugs 8. Patients with previous allogeneic stem cell or parenchymal organ transplantation 9. Having a mental illness or any other condition that renders treatment non-compliant 10. Patients unable or unwilling to sign the informed consent form 11. The investigator considered that the patient's condition may affect compliance with the protocol or make participation in this study unsuitable.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 2-year Disease-Free Survival | 24 months | DFS was defined as the time from the start of the treatment to either the date of disease recurrence or death (whatever the cause) as assessed by the investigator. Recurrence of disease was defined as local regional recurrence, a distant (metastatic) recurrence, or a second primary cancer. Occurrence of a second extra-pulmonary malignancy was considered to be an event. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | 60 months | OS was defined as the time from the start of treatment to the date of death. |
| Adverse events | 24 months | Incidence of AE/SAE which has been confirmed correlation with treatment. |
Countries
China
Contacts
Primary ContactWen-Zhao Zhong, MD
Outcome results
None listed